Free · 13,591 studies indexed

lighttherapyresearch.com is a free index of research on photobiomodulation and light therapy, gathered from the world’s journals and trial registries.

Sections
Eye, Ear & Vision

Ranibizumab after laser photocoagulation failure in retinopathy of prematurity (ROP) treatment

The unsatisfactory results of this study elicited a change in the ROP treatment protocol in our medical centre. The study gives an insight into anatomical and functional outcomes of ROP treatment in the Central and Eastern European population.

Excerpt from the paper’s abstract. Read the full paper for the details.

AI-generated summary

The authors retrospectively reviewed medical records of 53 eyes in 28 infants with severe retinopathy of prematurity treated first with laser photocoagulation and later with intravitreal ranibizumab. They report that ranibizumab could be considered in selected cases where laser failed, and that retinal detachment occurred in 22.6% of eyes. The study was retrospective, and the authors describe the outcomes as unsatisfactory, which led to a change in their treatment protocol.

Participants
28
Who or what was studied
Infants with severe retinopathy of prematurity whose eyes were treated with laser photocoagulation followed by deferred intravitreal ranibizumab (53 eyes of 28 infants), mean gestational age 25 weeks and mean birthweight 790 g.
Limits stated in the abstract
The study was a retrospective review of medical records from a single centre, and the abstract describes the outcomes as unsatisfactory.

Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.

Abstract

The purpose of this study was to investigate the anatomical and functional outcomes of the two-stage treatment of severe retinopathy of prematurity (ROP) using laser photocoagulation and intravitreal ranibizumab injection. The medical records of 53 eyes of 28 infants treated by conventional laser photocoagulation with deferred intravitreal 0.25 mg/0.025 mL ranibizumab injection were analysed. All patients had at least 11 months of follow-up. In the analysed group, the mean gestational age at birth was 25 weeks and mean birthweight was 790 g. The mean time of laser photocoagulation was 34 weeks of postmenstrual age (PMA). Ranibizumab injection was performed on average at 37 weeks of PMA. The mean time between interventions was 19 days. Retinal detachment occurred in 12 eyes (22.6%), in three children bilaterally. Visual responses were obtained in 23 of 28 treated children. Our results indicate that ranibizumab injection can be taken into consideration in the selected cases of laser photocoagulation failure. The unsatisfactory results of this study elicited a change in the ROP treatment protocol in our medical centre. The study gives an insight into anatomical and functional outcomes of ROP treatment in the Central and Eastern European population.

Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.

How to read a trial: what to check before relying on this kind of research.

Terms in this paper: Laser. Each links to its definition in the glossary.

A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.

Related studies